OTLK - OTLK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Case | Benzinga
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Outlook Therapeutics, Inc. (NASDAQ:OTLK) securities between December 29, 2022 and August 29, 2023, inclusive (the "Class Period"), have until January 2, 2024 to seek appointment as lead plaintiff of the Outlook Therapeutics class action lawsuit. Captioned Alsaidi v. Outlook Therapeutics, Inc., No. 23-cv-21862 (D.N.J.), the Outlook Therapeutics class action lawsuit charges Outlook Therapeutics as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Outlook Therapeutics class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-outlook-therapeutics-inc-class-action-lawsuit-otlk.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Outlook Therapeutics' lead product candidate is ONS-5010, an ophthalmic formulation of the antibody bevacizumab for the treatment of wet age-related macular degeneration ("wet AMD") and other retina diseases.
The Outlook Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) there was ...